The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) monotherapy, followed by chemotherapy, followed by pembrolizumab consolidation. The primary hypothesis of the study is that the complete response (CR) rate at the end of study intervention according to Lugano 2014 response criteria is higher than conventional chemotherapy.
| Condition | Classical Hodgkin Lymphoma |
|---|---|
| Treatment | cyclophosphamide, etoposide, prednisone, Pembrolizumab, Bleomycin, vincristine, doxorubicin, dacarbazine, procarbazine, Vinblastine |
| Clinical Study Identifier | NCT05008224 |
| Sponsor | Merck Sharp & Dohme LLC |
| Last Modified on | 20 July 2022 |
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.